Sigrid Therapeutics Selected to Present Results from STAR Proof of Concept Trial at American Diabetes Association 80[th] Scientific Sessions
Stockholm, Sweden — June 8th, 2020 — Sigrid Therapeutics (Sigrid) today announced that the Company’s STAR study results have been selected for presentation at the American Diabetes Associations 80th Scientific Session on June 12-16, 2020 in Chicago, Ilinois. The STAR study (clinicaltrials.org ID no. NCT03823027) was an open-label, single-arm, multicenter study with the primary objective of demonstrating a reduction in long term blood sugar, as measured by HbA1c, in prediabetics after 12 weeks of treatment. The results of the trial have the potential to impact patient care of prediabetics worldwide. The virtual presentation will be conducted by Sigrid’s Senior Clinical Project Manager, Anna Uddén. It will also be published online on the journal Diabetes® website.
“We are delighted to have been selected to present and discuss our recent clinical results at the world’s largest and most prestigious diabetes meeting. This selection reflects the increasing interest in our approach from the global diabetes community,” says Sigrid CEO and Co-founder Sana Alajmovic.
The American Diabetes Association 80th Scientific Sessions
Title: Engineered Silica Particles Reduce HbA1c in Persons with Prediabetes
Date/Time: Saturday, June 13, 2020 10:00 AM US/CENTRAL
Location: Virtual presentation
Presentation Number: 1079-P
About the American Diabetes Association (ADA) Scientific Sessions
The American Diabetes Association’s Scientific Sessions offers researchers and health care professionals from around the world the unique opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care. Some 15,000 people are expected to attend. https://professional.diabetes.org/scientific-sessions
About Sigrid Therapeutics
Sigrid Therapeutics (Sigrid) is a clinical-stage technology startup pioneering a new class of engineered materials to prevent and treat metabolic disease and disorders, including type 2 diabetes. The Company’s lead product candidate, SiPore15, is an orally-administered medical device based on the Company’s proprietary platform technology, SiPore. Designed to act locally in the gut, SiPore15, consists of precisely engineered micron-sized silica particles with tailored porosity. Clinical data confirms SiPore15’s beneficial effects on a range of metabolic parameters and its excellent safety profile. Upon its approval, SiPore15 will be the first medical device available for reduction of blood sugar levels in people at risk of developing type 2 diabetes.
For further information, please contact:
Sana Alajmovic – CEO, Sigrid Therapeutics AB
Telephone: +46 72 389 3396
+44 7711 821527